Lexicon Pharmaceuticals Holds Annual Stockholder Meeting

Lexicon Pharmaceuticals ( (LXRX) ) has provided an announcement.

On June 2, 2025, Lexicon Pharmaceuticals held its annual meeting of stockholders to vote on several key proposals. The meeting resulted in the election of Class I Directors, amendments to the company’s equity incentive plans, approval of a potential reverse stock split, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2025. These decisions reflect strategic moves to enhance corporate governance and financial management, potentially impacting shareholder value and market perception.

The most recent analyst rating on (LXRX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lexicon Pharmaceuticals stock, see the LXRX Stock Forecast page.

Spark’s Take on LXRX Stock

According to Spark, TipRanks’ AI Analyst, LXRX is a Neutral.

Lexicon Pharmaceuticals’ overall score is driven by the positive sentiment and strategic advancements highlighted in the earnings call, such as the partnership with Novo Nordisk. However, ongoing financial performance challenges, including profitability and liquidity concerns, weigh heavily on the score. Technical indicators show mild positive momentum, but valuation remains a concern with a negative P/E ratio.

To see Spark’s full report on LXRX stock, click here.

More about Lexicon Pharmaceuticals

Average Trading Volume: 14,357,705

Technical Sentiment Signal: Sell

Current Market Cap: $225.8M

Learn more about LXRX stock on TipRanks’ Stock Analysis page.